Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920, a Novel Engineered CD40L Antagonist, at the 2018 ACR/ARHP Annual Meeting VIB4920 demonstrated proof-of-concept in a Phase 1b multiple-ascending dose study October...
Continue Reading
© 2018 Viela Bio. All rights reserved.